New York Blood Center, Inc.
BiotechNew York Blood Center, Inc. is a biotechnology company with 1 FDA-approved products.
New York Blood Center, Inc.'s Key Drugs
New York Blood Center, Inc.'s core commercial portfolio centers on Hemacord — its most strategically important drugs approved in the last 15 years.
New York Blood Center, Inc.'s Recent FDA Approvals
New NDA/BLA approvals for New York Blood Center, Inc. over the last two years — novel drugs only, excluding generics and label supplements.
New York Blood Center, Inc.'s Therapeutic Areas
Disease areas where New York Blood Center, Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
New York Blood Center, Inc. Pipeline Snapshot
Active clinical trials for New York Blood Center, Inc. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Hemacord leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2011-11-09
- Latest
- 2011-11-09
- Applications
- 1